|34.89 2.31 (7.09%)||12-01 16:00|
|Targets||6-month :||43.45||1-year :||47.42|
|Resists||First :||37.2||Second :||40.59|
|Supports||First :||31.7||Second :||26.38|
|MAs||MA(5) :||33.09||MA(20) :||34.05|
|MA(100) :||49.9||MA(250) :||55.41|
|MACD||MACD :||-2||Signal :||-2.5|
|%K %D||K(14,3) :||27.8||D(3) :||19.3|
|52-week||High :||79.65||Low :||28.51|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRTA ] has closed below upper band by 16.2%. Bollinger Bands are 57% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||34.97 - 35.22||35.22 - 35.41|
|Low:||31.53 - 31.77||31.77 - 31.96|
|Close:||34.55 - 34.95||34.95 - 35.27|
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||54 (M)|
|Held by Insiders||3.959e+007 (%)|
|Held by Institutions||4.7 (%)|
|Shares Short||4,390 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||-52 %|
|Operating Margin||12.1 %|
|Return on Assets (ttm)||-10.9 %|
|Return on Equity (ttm)||-14.4 %|
|Qtrly Rev. Growth||5 %|
|Gross Profit (p.s.)||1123.4|
|Sales Per Share||3.20409e+008|
|Qtrly Earnings Growth||-1.4 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-88 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||1.33|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|